These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Circulating tumour cells: insights into tumour heterogeneity. Hayes DF; Paoletti C J Intern Med; 2013 Aug; 274(2):137-43. PubMed ID: 23844916 [TBL] [Abstract][Full Text] [Related]
4. Tumor heterogeneity is fundamental to the tumor ecosystem. Heppner GH; Shekhar M Oncology (Williston Park); 2014 Sep; 28(9):780-1. PubMed ID: 25224476 [No Abstract] [Full Text] [Related]
5. Tumor heterogeneity and implications for clinical practice. Chu E Oncology (Williston Park); 2014 Sep; 28(9):726, 741. PubMed ID: 25224470 [No Abstract] [Full Text] [Related]
6. Tumor heterogeneity: the Lernaean hydra of oncology? Janiszewska M; Beca F; Polyak K Oncology (Williston Park); 2014 Sep; 28(9):781-2, 784. PubMed ID: 25224477 [No Abstract] [Full Text] [Related]
7. The epidemiology and clinical implications of genetic variation in prostate cancer. Helfand BT; Catalona WJ Urol Clin North Am; 2014 May; 41(2):277-97. PubMed ID: 24725490 [TBL] [Abstract][Full Text] [Related]
8. Genetic and phenotypic heterogeneity of human malignancies: finding order in chaos. Shackney SE; Shankey TV Cytometry; 1995 Sep; 21(1):2-5. PubMed ID: 8529466 [TBL] [Abstract][Full Text] [Related]
9. [Molecular markers having a prognostic or therapeutic value in cancer]. Brousset P Ann Pathol; 2008 Nov; 28 Spec No 1(1):S69-70. PubMed ID: 18984307 [No Abstract] [Full Text] [Related]
10. Molecular pathology in real time. Ryška A Cancer Metastasis Rev; 2016 Mar; 35(1):129-40. PubMed ID: 26931654 [TBL] [Abstract][Full Text] [Related]
11. Understanding genomic alterations in cancer genomes using an integrative network approach. Wang E Cancer Lett; 2013 Nov; 340(2):261-9. PubMed ID: 23266571 [TBL] [Abstract][Full Text] [Related]
12. The challenge of intratumour heterogeneity in precision medicine. Seoane J; De Mattos-Arruda L J Intern Med; 2014 Jul; 276(1):41-51. PubMed ID: 24661605 [TBL] [Abstract][Full Text] [Related]
13. Discovering causes and cures for cancer from gene expression analysis. Weeraratna AT Ageing Res Rev; 2005 Nov; 4(4):548-63. PubMed ID: 16243590 [TBL] [Abstract][Full Text] [Related]
14. Micromarkers: miRNAs in cancer diagnosis and prognosis. Ferracin M; Veronese A; Negrini M Expert Rev Mol Diagn; 2010 Apr; 10(3):297-308. PubMed ID: 20370587 [TBL] [Abstract][Full Text] [Related]
15. The potential of molecular screening. Ahrendt SA; Sidransky D Surg Oncol Clin N Am; 1999 Oct; 8(4):641-56, vi. PubMed ID: 10452932 [TBL] [Abstract][Full Text] [Related]
16. Cancer heterogeneity and "the struggle for existence": diagnostic and analytical challenges. Horswell S; Matthews N; Swanton C Cancer Lett; 2013 Nov; 340(2):220-6. PubMed ID: 23142290 [TBL] [Abstract][Full Text] [Related]
17. Organ-specific markers in circulating tumor cell screening: an early indicator of metastasis-capable malignancy. Paterlini-Bréchot P Future Oncol; 2011 Jul; 7(7):849-71. PubMed ID: 21732757 [TBL] [Abstract][Full Text] [Related]
18. [DNA methylation: potential for diagnosis, prognosis and therapy--prediction in oncology]. Haedicke W; Lesche R Verh Dtsch Ges Pathol; 2006; 90():39-45. PubMed ID: 17867578 [TBL] [Abstract][Full Text] [Related]
19. Intratumoral genomic heterogeneity in primary head and neck cancer and corresponding metastases detected by dual-FISH. Götte K; Schäfer C; Riedel F; Arens N; Hörmann K Oncol Rep; 2004 Jan; 11(1):17-23. PubMed ID: 14654897 [TBL] [Abstract][Full Text] [Related]
20. Pan-cancer analysis of intratumor heterogeneity as a prognostic determinant of survival. Morris LG; Riaz N; Desrichard A; Şenbabaoğlu Y; Hakimi AA; Makarov V; Reis-Filho JS; Chan TA Oncotarget; 2016 Mar; 7(9):10051-63. PubMed ID: 26840267 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]